Hua Peng
0000-0002-2482-5475
13 papers found
Refreshing results…
Towards developing a variant-proof SARS-CoV-2 vaccine
Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance
An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery
A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains
A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors
Broad neutralization against SARS-CoV-2 variants induced by a next-generation protein vaccine V-01
Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2
The AIM2 and NLRP3 inflammasomes trigger IL-1–mediated antitumor effects during radiation
PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade
Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3–CD8+ T cells
Author Correction: A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control
Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B
A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control
Missing publications? Search for publications with a matching author name.